Geode Capital Management
GOSS icon

Geode Capital Management’s Gossamer Bio GOSS Stock Holding History

Geode Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$409K Sell
2,481,605
-2,458,086
-50% -$686K ﹤0.01% 3683
2026
Q1 		$1.62M Buy
4,939,691
+66,977
+1% +$105K ﹤0.01% 3204
2025
Q4 		$15.1M Buy
4,872,714
+183,183
+4% +$523K ﹤0.01% 2167
2025
Q3 		$12.3M Buy
4,689,531
+134,451
+3% +$296K ﹤0.01% 2295
2025
Q2 		$5.6M Buy
4,555,080
+2,282,632
+100% +$2.49M ﹤0.01% 2672
2025
Q1 		$2.5M Buy
2,272,448
+21,987
+1% +$25.4K ﹤0.01% 2957
2024
Q4 		$2.04M Buy
2,250,461
+38,084
+2% +$32.6K ﹤0.01% 3116
2024
Q3 		$2.18M Sell
2,212,377
-71,241
-3% -$68.5K ﹤0.01% 3094
2024
Q2 		$2.06M Hold
2,283,618
– – ﹤0.01% 3120
2024
Q1 		$2.7M Buy
2,283,618
+10,693
+0.5% +$11.8K ﹤0.01% 2998
2023
Q4 		$2.07M Buy
2,272,925
+107,346
+5% +$79.3K ﹤0.01% 3090
2023
Q3 		$1.8M Buy
2,165,579
+1,396,420
+182% +$1.61M ﹤0.01% 3103
2023
Q2 		$923K Sell
769,159
-577,100
-43% -$719K ﹤0.01% 3390
2023
Q1 		$1.7M Buy
1,346,259
+51,145
+4% +$97.9K ﹤0.01% 3104
2022
Q4 		$2.81M Buy
1,295,114
+36,345
+3% +$299K ﹤0.01% 2927
2022
Q3 		$15.1M Buy
1,258,769
+232,714
+23% +$2.89M ﹤0.01% 1950
2022
Q2 		$8.59M Sell
1,026,055
-3,772
-0.4% -$29.2K ﹤0.01% 2359
2022
Q1 		$8.94M Buy
1,029,827
+16,744
+2% +$161K ﹤0.01% 2424
2021
Q4 		$11.5M Buy
1,013,083
+17,322
+2% +$206K ﹤0.01% 2354
2021
Q3 		$12.5M Buy
995,761
+73,467
+8% +$676K ﹤0.01% 2306
2021
Q2 		$7.49M Buy
922,294
+76,700
+9% +$665K ﹤0.01% 2659
2021
Q1 		$7.82M Buy
845,594
+68,597
+9% +$692K ﹤0.01% 2523
2020
Q4 		$7.51M Sell
776,997
-11,710
-1% -$115K ﹤0.01% 2350
2020
Q3 		$9.79M Buy
788,707
+37,129
+5% +$492K ﹤0.01% 1962
2020
Q2 		$9.77M Buy
751,578
+159,982
+27% +$2.01M ﹤0.01% 1932
2020
Q1 		$6M Buy
591,596
+64,191
+12% +$838K ﹤0.01% 2032
2019
Q4 		$8.24M Buy
527,405
+27,310
+5% +$550K ﹤0.01% 2144
2019
Q3 		$8.4M Buy
500,095
+257,106
+106% +$5.11M ﹤0.01% 2057
2019
Q2 		$5.39M Buy
242,989
+34,992
+17% +$669K ﹤0.01% 2333
2019
Q1 		$4.51M Buy
+207,997
New +$4.34M ﹤0.01% 2393

Other funds holding GOSS

D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Geode Capital Management's GOSS Position: Q2 2026 in Review

Geode Capital Management reduced its Gossamer Bio (GOSS) stake by 50% in Q2 2026, selling an estimated $686K and leaving 2,481,605 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #3683.

Geode Capital Management first reported a position in GOSS in Q1 2019 and has held it in 30 quarters since. The position peaked at $15.1M in Q4 2025. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Geode Capital Management held 2,481,605 shares of Gossamer Bio worth $409K as of Q2 2026.
  • Geode Capital Management sold 2,458,086 Gossamer Bio shares in Q2 2026, an estimated $686K.
  • Gossamer Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3683 holding.
  • Geode Capital Management first reported a position in Gossamer Bio in Q1 2019 and has held it in 30 quarters since.
  • Geode Capital Management's Gossamer Bio position peaked at $15.1M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.